This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Zipf, T. F. Articles by Levy, R. Search for Related Content PubMed PubMed Citation Articles by Zipf, T. F. Articles by Levy, R.

Definition of the High-Risk Acute Lymphoblastic Leukemia Patient by Immunological Phenotyping with Monoclonal Antibodies¹

Howard Hughes Medical Institute Laboratories [R. I. F., J. D., R. L.], Department of Medicine/Oncology [R. I. F., J. D., R. L.], and Department of Pediatrics [T. F. Z.], Stanford University Medical Center, Stanford, California 94305, and Division of Hematology/Oncology, Chilldren's Hospital at Stanford, Palo Alto, California 94304 [T. F. Z.]

An accurate method of classification of the surface membrane characteristics of blast cells from patients with acute lymphoblastic leukemia would allow a more definitive study of the nature of this disease. Monoclonal antibodies have been produced to the surface antigens of leukemia blasts from a patient with high-risk acute lymphoblastic leukemia. Two antibodies of interest were obtained from this immunization. These two, in combination with a monoclonal antibody with anti-la specificity, have been used to obtain surface phenotypes for patients with childhood acute lymphoblastic leukemia. Preliminary results indicate that the definition of a high-risk group, using these antibodies, is possible.

¹ Presented at the Conference on Cell Markers in Acute Leukemia, March 4 and 5, 1980, Bethesda, Md.

² Present address: Oncology Research Group, Faculty of Medicine, University of Calgary, 2920 24th Avenue N. W., Calgary, Alberta T2N 1N4, Canada.

³ To whom requests for reprints should be addressed, at Department of Medicine/Oncology, Stanford University, Stanford, Calif. 94305.